Indications: Olaparib (INN) 150 mg is prescribed for various cancers:

• Ovarian cancer: as maintenance therapy post platinum-based chemotherapy.
• Breast cancer: for metastatic HER2-negative breast cancer in patients with BRCA mutations.
• Pancreatic cancer: for metastatic cases in patients with BRCA mutations after chemotherapy.

Pharmacology: Olaparib blocks PARP enzymes, disrupting DNA repair, particularly in cells with BRCA mutations, inducing cancer cell death.

Dosage and Administration: The standard dose of Olaparib is 300 mg twice daily, but for Olaparib 150 mg tablets, it’s usually one tablet twice daily. Dosage adjustments might be needed based on individual response and side effects, taken with or without food.

Interactions: Olaparib can interact with other medications, so patients should inform their healthcare providers about all medications, including supplements.

Side Effects: Common side effects include nausea, vomiting, fatigue, anemia, reduced appetite, diarrhea, and abdominal pain. Serious effects may include bone marrow suppression and increased cancer risks.

Precautions and Warnings: Olaparib may induce bone marrow suppression and increased cancer risks, requiring regular blood tests and vigilant monitoring.

Overdose Effects: Overdose management involves supportive measures, as there’s no specific antidote. Treatment focuses on alleviating symptoms.